A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
Status:
Completed
Trial end date:
2015-06-12
Target enrollment:
Participant gender:
Summary
This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled
study will evaluate the efficacy and safety of RO4602522 in participants with moderate
severity Alzheimer's disease. Participants who are taking background therapy of
acetylcholinesterase inhibitors (AChEI) alone or in combination with memantine for at least 4
months before screening will be randomized to receive either one of two doses of RO4602522 or
placebo for 12 months.